Dose finding in aspergillosis

Claudio Viscoli, Matteo Bassetti

Research output: Contribution to journalArticle

Abstract

Invasive aspergillosis (IA) continues to represent a significant challenge for physicians in charge of immunocompromised patients. Voriconazole, caspofungin, itraconazole, and the different formulations of amphotericin B (AmB) are all approved for therapy of IA. To collect information on the effect of high dose of antifungals in the treatment of IA, data from the available medical literature were reviewed. For AmB there are no data demonstrating any better clinical activity of doses higher than standard. For liposomal-AmB preliminary data seem to show that high doses are not more efficacious than the standard dose, and it is probably more toxic. Anecdotal data of itraconazole suggest that high dosages might be feasible and it has been associated with good clinical results. Unpublished data about voriconazole suggest the absence of any better activity of high plasma concentrations. For caspofungin the efficacy of higher dosage did not seem to be better than that obtained with the traditional dosage. Prospective studies are required, because many confounding factors may obscure the effects of the higher dosages when data are retrieved retrospectively.

Original languageEnglish
Pages (from-to)299-303
Number of pages5
JournalMedical Mycology
Volume44
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Sep 2006

Fingerprint

caspofungin
Aspergillosis
aspergillosis
Itraconazole
Amphotericin B
dosage
amphotericin B
Poisons
Immunocompromised Host
itraconazole
Prospective Studies
Physicians
Therapeutics
prospective studies
physicians
Voriconazole
therapeutics

Keywords

  • Antifungal
  • Aspergillosis
  • Dose
  • High
  • Invasive

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • veterinary(all)
  • Microbiology

Cite this

Dose finding in aspergillosis. / Viscoli, Claudio; Bassetti, Matteo.

In: Medical Mycology, Vol. 44, No. SUPPL. 1, 09.2006, p. 299-303.

Research output: Contribution to journalArticle

Viscoli, Claudio ; Bassetti, Matteo. / Dose finding in aspergillosis. In: Medical Mycology. 2006 ; Vol. 44, No. SUPPL. 1. pp. 299-303.
@article{1a61030fbf774c2abb33754595382c54,
title = "Dose finding in aspergillosis",
abstract = "Invasive aspergillosis (IA) continues to represent a significant challenge for physicians in charge of immunocompromised patients. Voriconazole, caspofungin, itraconazole, and the different formulations of amphotericin B (AmB) are all approved for therapy of IA. To collect information on the effect of high dose of antifungals in the treatment of IA, data from the available medical literature were reviewed. For AmB there are no data demonstrating any better clinical activity of doses higher than standard. For liposomal-AmB preliminary data seem to show that high doses are not more efficacious than the standard dose, and it is probably more toxic. Anecdotal data of itraconazole suggest that high dosages might be feasible and it has been associated with good clinical results. Unpublished data about voriconazole suggest the absence of any better activity of high plasma concentrations. For caspofungin the efficacy of higher dosage did not seem to be better than that obtained with the traditional dosage. Prospective studies are required, because many confounding factors may obscure the effects of the higher dosages when data are retrieved retrospectively.",
keywords = "Antifungal, Aspergillosis, Dose, High, Invasive",
author = "Claudio Viscoli and Matteo Bassetti",
year = "2006",
month = "9",
doi = "10.1080/13693780600838264",
language = "English",
volume = "44",
pages = "299--303",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Dose finding in aspergillosis

AU - Viscoli, Claudio

AU - Bassetti, Matteo

PY - 2006/9

Y1 - 2006/9

N2 - Invasive aspergillosis (IA) continues to represent a significant challenge for physicians in charge of immunocompromised patients. Voriconazole, caspofungin, itraconazole, and the different formulations of amphotericin B (AmB) are all approved for therapy of IA. To collect information on the effect of high dose of antifungals in the treatment of IA, data from the available medical literature were reviewed. For AmB there are no data demonstrating any better clinical activity of doses higher than standard. For liposomal-AmB preliminary data seem to show that high doses are not more efficacious than the standard dose, and it is probably more toxic. Anecdotal data of itraconazole suggest that high dosages might be feasible and it has been associated with good clinical results. Unpublished data about voriconazole suggest the absence of any better activity of high plasma concentrations. For caspofungin the efficacy of higher dosage did not seem to be better than that obtained with the traditional dosage. Prospective studies are required, because many confounding factors may obscure the effects of the higher dosages when data are retrieved retrospectively.

AB - Invasive aspergillosis (IA) continues to represent a significant challenge for physicians in charge of immunocompromised patients. Voriconazole, caspofungin, itraconazole, and the different formulations of amphotericin B (AmB) are all approved for therapy of IA. To collect information on the effect of high dose of antifungals in the treatment of IA, data from the available medical literature were reviewed. For AmB there are no data demonstrating any better clinical activity of doses higher than standard. For liposomal-AmB preliminary data seem to show that high doses are not more efficacious than the standard dose, and it is probably more toxic. Anecdotal data of itraconazole suggest that high dosages might be feasible and it has been associated with good clinical results. Unpublished data about voriconazole suggest the absence of any better activity of high plasma concentrations. For caspofungin the efficacy of higher dosage did not seem to be better than that obtained with the traditional dosage. Prospective studies are required, because many confounding factors may obscure the effects of the higher dosages when data are retrieved retrospectively.

KW - Antifungal

KW - Aspergillosis

KW - Dose

KW - High

KW - Invasive

UR - http://www.scopus.com/inward/record.url?scp=33749525677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749525677&partnerID=8YFLogxK

U2 - 10.1080/13693780600838264

DO - 10.1080/13693780600838264

M3 - Article

AN - SCOPUS:33749525677

VL - 44

SP - 299

EP - 303

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - SUPPL. 1

ER -